{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:45:16Z","timestamp":1784940316725,"version":"3.55.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is a rare hereditary disease leading to end-stage renal failure in approximately half of patients by seventy years of age. It is important to continuously take tolvaptan to control disease progression. However, adherence to tolvaptan in a real-world setting, rather than randomized controlled trials (RCTs), has not been sufficiently reported. We aimed to investigate tolvaptan persistence among patients with ADPKD using a large claims database. Using the Shizuoka Kokuho Database, we identified patients diagnosed with ADPKD who were prescribed tolvaptan from March 2014\u2013September 2018 in Japan. The persistence rate of tolvaptan medication was estimated by Kaplan\u2013Meier analysis, and patient background factors associated with treatment discontinuation were exploratively evaluated with log-rank tests. We identified 1714 eligible patients with ADPKD, and among them, 25 patients used tolvaptan medication. We followed up these patients, whose median treatment duration was 21 months. The persistence rates at 12, 24, and 36 months were estimated to be 70.8% (95% confidence interval: 48.2\u201393.4), 46.5% (23.2\u201366.9), and 38.7% (16.4\u201360.8), respectively. In the exploratory analysis, there were no factors that were obviously associated with tolvaptan discontinuation. The persistence rate of tolvaptan in patients with ADPKD in a real-world setting may be lower than that in previous RCTs. Our innovative method, particularly in Japan, to analyze adherence using large claims data should change the way clinical epidemiological research and health policies of rare diseases are designed in the future.<\/jats:p>","DOI":"10.1097\/md.0000000000030923","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T15:11:07Z","timestamp":1665414667000},"page":"e30923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: A retrospective cohort study using Shizuoka Kokuho Database"],"prefix":"10.1097","volume":"101","author":[{"given":"Ryuta","family":"Saito","sequence":"first","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"},{"name":"Department of Health Policy and Management, School of Medicine, Keio University, Shinanomachi, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3337-7595","authenticated-orcid":false,"given":"Hiroyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"},{"name":"Department of Health Policy and Management, School of Medicine, Keio University, Shinanomachi, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"},{"name":"Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kumamaru","sequence":"additional","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"},{"name":"Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"},{"name":"Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, School of Medicine, Keio University, Shinanomachi, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Miyachi","sequence":"additional","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Miyata","sequence":"additional","affiliation":[{"name":"Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka City, Japan"},{"name":"Department of Health Policy and Management, School of Medicine, Keio University, Shinanomachi, Shinjuku-ku, Tokyo, Japan"},{"name":"Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000045214","article-title":"Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan.","volume":"80","author":"Higashihara","year":"1998","journal-title":"Nephron"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease.","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease.","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease.","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3: 4.","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database.","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease.","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20250504","first-page":"915","article-title":"Adverse drug events: identification and attribution.","volume":"21","author":"Rogers","year":"1987","journal-title":"Drug Intell Clin Pharm"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pds.4962","article-title":"Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.","volume":"29","author":"Wu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3999\/jscpt.46.185","article-title":"The current status of all-case surveillance study in Japan and factors influencing the judgment of its necessity.","volume":"46","author":"Mori","year":"2015","journal-title":"Rinsho Yakuri\/ Japanese J Clin Pharmacol Ther"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"20420986211065215","DOI":"10.1177\/20420986211065215","article-title":"Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan.","volume":"12","author":"Kondo","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics.","volume":"58","author":"Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41581-021-00439-x","article-title":"Big data in nephrology.","volume":"17","author":"Kaur","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0149-2918(97)80122-1","article-title":"The use of claims databases for outcomes research: rationale, challenges, and strategies.","volume":"19","author":"Motheral","year":"1997","journal-title":"Clin Ther"},{"key":"R19-20250504","first-page":"449","article-title":"Estimating medication persistency using administrative claims data.","volume":"11","author":"Sikka","year":"2005","journal-title":"Am J Manag Care"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/pds.1721","article-title":"Review on use of German health insurance medication claims data for epidemiological research.","volume":"18","author":"Hoffmann","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ckj\/sfaa076","article-title":"Health claims databases used for kidney research around the world.","volume":"14","author":"van Oosten","year":"2021","journal-title":"Clin Kidney J"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2188\/jea.JE20200480","article-title":"Data resource profile of Shizuoka Kokuho Database (SKDB) using integrated health- and care-insurance claims and health checkups: the Shizuoka study.","volume":"32","author":"Nakatani","year":"2022","journal-title":"J Epidemiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(11)60828-3","article-title":"Japanese universal health coverage: evolution, achievements, and challenges.","volume":"378","author":"Ikegami","year":"2011","journal-title":"Lancet"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"ofab068","DOI":"10.1093\/ofid\/ofab068","article-title":"Risk factors for pneumonia and death in adult patients with seasonal influenza and establishment of prediction scores: a population-based study.","volume":"8","author":"Miyashita","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41440-020-0440-2","article-title":"Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan.","volume":"43","author":"Nishimura","year":"2020","journal-title":"Hypertens Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ggi.13118","article-title":"Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society.","volume":"17","author":"Ouchi","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions.","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"R30-20250504","first-page":"62","article-title":"Epidemiological features of and screening for polycystic kidney disease in Japan.","volume":"6","author":"Yoshimoto","year":"2019","journal-title":"Ningen Dock Int"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10157-021-02100-0","article-title":"Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.","volume":"25","author":"Mochizuki","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12199-017-0644-5","article-title":"Analysis of the evidence-practice gap to facilitate proper medical care for the elderly: investigation, using databases, of utilization measures for National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB).","volume":"22","author":"Nakayama","year":"2017","journal-title":"Environ Health Preventative Med"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.23876\/j.krcp.22.016","article-title":"Using the Mayo Imaging Classification to predict renal outcomes in Korean autosomal dominant polycystic kidney disease patients.","volume":"41","author":"Jung","year":"2022","journal-title":"Kidney Res Clin Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:40:28Z","timestamp":1746333628000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":29,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030923","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}